eran eden

Father, Husband, Entrepreneur, Scientist, Human being. Co-founder and CEO, MeMed ( Host response leader, solving BIG medical problems

[eran eden @eraneden]

🚨 When it rains, it pours! 🚨

Three peer-reviewed studies just came out, further validating #MeMedBV. Highlights include:
63% reduction in unnecessary antibiotics & fewer hospitalizations outperforming standard of care
See: https://t.co/24PmbDIT1I
#AMR #Sepsis #Hostresponse

[eran eden @eraneden]

Excited to welcome an extraordinary group of experts to join MeMed ’s advisory team!

Dave Hickey, a leader in the IVD industry,
Dr. David Shulkin, former U.S. Secretary of Veterans Affairs
Prof. Beat Müller, pioneer in sepsis care
for more see: https://t.co/ZNNgt33YfI

[eran eden @eraneden]

Thrilled to share that our MeMed Severity has been granted the prestigious FDA Breakthrough Device Designation! https://t.co/qjW4YlS4fP
#Sepsis #MeMedSeverity #hostresponse #Diagnostics

[eran eden @eraneden]

Another significant milestone! MeMed has attained #IVDR certification by the notified body TÜV SÜD for commercialization of #MeMedBV® in Europe under the new EU regulations.

Big thanks to Olga, Eli, Sharon, Harel, Sally, Efrat and the rest of the MeMeds that made this happen.

[eran eden @eraneden]

@memeddx @OHadomi Welcome on board Scott! Looking forward to working closely and pushing the envelope of the host-response field.

[MeMed @memeddx]

📢 MeMed continues to enhance its Board of Directors with the addition of Scott Garrett. Scott’s addition further bolsters our leadership team after welcoming @OHadomi and Peter Scheu.
https://t.co/vPvEegWAJW

[eran eden @eraneden]

Excited to share NEW study published in Pediatrics, enrolling >2,000 children, showing high performance of MeMed BV in distinguishing bacterial vs viral infections. Another step towards better-informed treatment decisions to fight #amr

Full article: https://t.co/6X0NQLjnQA

[eran eden @eraneden]

@memeddx @ESCMID @EU_Commission New study published in journal Clinical Microbiology and Infection finds high performance of MeMed BV in elderly patients with Lower Respiratory Tract infections. Another important milestone in the fight against #AMR & making MeMed BV part of routine care https://t.co/YBzckbltCM

[MeMed @memeddx]

♨️♨️♨️MeMed BV's remarkable accuracy in diagnosing bacterial/viral LRTI in adults regardless of age, comorbidities (including #COPD) or PCR results. Outperformed CRP & PCT in differentiating bacterial/viral infections. #MedTech @ESCMID @EU_Commission https://t.co/XuZ1XChV81

[Or-ly Barlev 🎗 אור-לי ברלב @orlybarlev]

לא פחות ממדהים - למעלה מ-50 קבוצות וארגונים לוקחים חלק בהפגנת הענק המרכזית ב-קפלן ת"א ובהפגנות בירושלים, חיפה, ב"ש ומודיעין:
עורכי דין, רופאים, הייטקיסטים, הקהילה הגאה, סטודנטים, כלכלנים, אנשי חינוך, אנשי מע' הביטחון לשעבר, אנשי אקדמיה, תנועות נוער ועוד ועוד, שרשור!

[MeMed @memeddx]

Join us next week as we discuss using MeMed BV® in patients with suspected acute infection, with Dr. Adi Klein, Head of Pediatrics at Hillel Yaffe Medical Center in Hadera, Israel.
Register Now https://t.co/7jO2FcYF1y
#AMR #AntibioticResistance

[eran eden @eraneden]

Honored to be named among ‘Fierce 15’ Medtech Companies of the year. Congrats to the fantastic @memeddx team!
Find out more at: https://t.co/tBiiXKBB1A

[Chamath Palihapitiya @chamath]

Lots of chatter after Biden's comments re. social media's impact on mental health.

Is social media the 21st century tobacco? Should it be regulated?

Re-upping this from last year:

[eran eden @eraneden]

Antimicrobial resistance – the Silent Pandemic doesn’t receive much PR. But it has become a leading cause of death worldwide, potentially much larger than HIV and malaria. A recent Lancet paper is yet another wakeup call:
https://t.co/j62uh1NL2Y

[MeMed @memeddx]

We're pleased to announce that we have successfully closed a $93M financing round to scale up manufacturing, accelerate commercialization and expand our pioneering host immune response product portfolio.

Read the press release: https://t.co/ONOt7UWXbW

#IDTwitter #HostResponse

[eran eden @eraneden]

The closing of over $90M financing round represents a significant milestone for @memeddx. Congratulations to #TeamMeMed for all the hard work!

https://t.co/4og1bqYPAm

[eran eden @eraneden]

Thrilled to share that FDA cleared the first technology to distinguish between bacterial and viral infections using the body’s immune response - our very own #MeMed BV test and #MeMed Key platform. It’s been a decade long journey and the best is yet to come... exciting times!

[MeMed @memeddx]

BREAKING NEWS! MeMed BV® and MeMed Key® have been granted FDA clearance. FDA clears the first technology of its kind to distinguish between bacterial and viral infections using the body’s immune response. Read the full press release here: https://t.co/pr1FEXGOaP
#fdacleared

[MeMed @memeddx]

Join Professor of Pharmacy, Infectious Diseases Pharmacist, Dr. Debra Goff, at the Presentation Theater at IDWEEK alongside MeMed CEO, Eran Eden, on September 16, 12:00- 1:00 pm EDT
https://t.co/3h7wF5TGjR

[eran eden @eraneden]

An exciting day for @memeddx ! Our #hostresponse test MeMed COVID-19 Severity™ has received the CE mark. Many thanks to our incredible team & collaborators globally for helping us achieve this milestone! #COVID19

[eran eden @eraneden]

medrxiv viewer https://t.co/il6ahLnsYl